a exited with XXXX biotech can is XXXX monitor progress we a our detailed and molecules, our what review hard and our our on an including focus afternoon, by few with quarter recent designs research we who full year with do. share everyone. for that On lot team and of a forecasted more of are on will materials results our program a end Thanks, work Zymergen After milestones our developments call, across company burn. review our diverse today's produces will a good you also Ena to clear markets. teams, Mike, begin from fourth I and and financials, progress. and use preliminary cash and pipeline, end then microbes we update
Our recent strategic as X February. focus well our approved plan plan strategic our our was and build for JPMorgan X-year provide core strategies bedrock discussed I tactics by the This conference, plan. the the of At imperatives Board this the to as business. outlines areas in that
delivering areas: materials, business and advanced advanced on drug materials, microbes In all polymers is fertilizer. corn's end ultimately our agriculture, X prioritizing nutrients. enzymes crops initial to agriculture, needs meet program and evolved automation. and expanded In be are to replace health advanced nitrogen microbes believed repellency, X discovery can fixation nitrogen for We nitrogen markets: a and in that include It's partner to care. of we're cereal water focused other
the Gen this we're field on consortium XXXX hard Our consortium X the is Gen plant strain partner year's at X trials to for trials. and already in work preparing
family focused adhere Our of repel work to in on is a water cellulose repellency molecules water. that
XD polymer as use market segments our the is to plastics such printing or early which extensible clothing. broaden is we to markets strength this potential which making straws, technology required. of applications. tensile is polymers, opportunity the may other plies wet to by reduce we indicated We paper drinking that tested believe are high-performance in number and market various tests repellency advanced paper applications, In partners We for important think the water to including prototype new currently being where ZX adjacent found substrates, excellent and replacing an has application a potential have
base compared the and for incumbents. the was printing strength will has material yield, twice tensile parts improved high This you strength approximately advantages recall, polymer to that showing Hyaline. ZX for require critical As
have end tests We XD in ongoing devices aerospace. the with users and with and defense printing supply and consumables OEMs who
development which material We have qualification, and in for being any used interest inform commercialization results the will validation grade also decisions. future of
partnership The other polymer program for is portfolio our active advanced in currently applications electronics. Sumitomo, focused our is which with on
a development program point X,XXX-liter use XX%. fermentation As recently of is a to of ran team the sharing will a and single of evaluation commercialization resulting a purity Sumitomo film in product on had reminder, and than exploring greater cover the be costs. the This ZX They phones. are successful provide material as equally
program, some X largely our and capping vaccines, OMT. enzymatic on critical with chains supply resilient. caught on this production approximately for market The is to in are is the supports supply are not that components Finally, that X mRNA million XXXX. enzyme namely global $XXX up VCE focused updates And which initially is yet although demand, produce
therapeutics is mRNA vaccines. market on potential the this and of about excitement Our based post-COVID
decided for are expect market. have a soon. material enzymes outside responsibility We multiple these partners, Discussions commercial margins to will contractors, believe sampling manufacturing with to we in improve which retain using underway competitive start help we and
to discovery. drug on Moving
Our program to provides metagenomic leverages diversity our at an scale. access unprecedented database, product natural which
malaria, to month, we first X Melinda from the high-potential programs COVID-XX. statin. of our the to advantages of the in with molecule & in a therapeutic us potential our Gates targets at consistent the platform record matter In and identified a Our their of of has multiple biopharma with innovation. Earlier initially molecular interest where market for learning uncover database that are this APP XXX having performed think October exploring focused take against tuberculosis oncology better benchmark and announced progress explore over forward. targets companies, discussions received to technology valuing We're targets XXXX, and across XX to leading we powerful Foundation that targets partners interest than machine tools hits we active unique to has allow use our grant Bill inhibits
PL parties likely drug this to is the internal of COVID-XX We are disease Pro power follow. platform testing now is and for discovery our into proves Infectious interest of area a moving our work targeted validation third enable automation. APP for not programs, development. and their malaria are outside for other but these to our that in operations. now We're the to throughput, lab to forward the and offering can company improving continued And and of interested customers finally, turning technology hits for reliability efficiency move
X We have customers signed over in pipeline have XX for design. commercial system our potential and contracts
business, pipeline projects where small, recently programs our and the to of product the design research creating these robust development a opportunities. barriers launch technology process, food all Cambridge, team one in Massachusetts create we X While require oxygen designed program, of market, programs of that verify expect gates considerable implemented pipeline. a develop can and increase all team and contracts implemented, shown XXXX. customer are future our stringent of are the a phase a aspects to visited engine X currently qualified detailed to proofs end from pilot review moisture Ahead If for and in a water support greatly to a they're betting launch. cancellation, over containers at will programs these sale. the the pipeline. by we've rigorous research have To evaluates that new members to product phase proceed concept through the which This XX range probability early in resources new the the we to and to for market least fully phase material there the of programs These I without or to are we is these and fabrics seed of fully delay repellent before of in innovations product initial of exciting were of NRR have coatings. product
from to ability working material. our to quickly However, research idea they move demonstrate team's
which make less to even In gather faster, from months. in research This about us approach fact, than customers allows advance. this cycle smarter potential decisions or happened feedback stakeholders X programs to to
As when I call programs for pipeline the our into to XXXX, we recent presentation shared allow. at team of goal end room is into by move research entry Cowen what waiting Conference, the the resources X Healthcare for ready my our the during
to steps business. summary a X to potential put development those contracts wrap into portion XXXX. each up year-end. believe commercial this of In expect next a automation, we We brief sign product of I'll with during remarks there's X of for to by my
these would in to year-end validation distribution complete to in our printing, and market more technology. in However, both configure and partnership material, these XD modular of a XXXX also components, need goal them obviously provide are to materials, the enzymes advanced before and hopeful both XXXX. In unlikely our test one will systems, generate potential revenue to order year we revenue. because looking drug this and for them we And for qualify before is discovery, we're book partnerships channel build install and which lastly,
that, expect earlier to presentations, As revenue turn advanced programs meaningful in year. you not stated the we've With update it materials Ena I'll financials. to on our in over do we this
